Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioNTech will buy Biotheus, gaining control of a cancer bispecific antibody that aims to improve on checkpoint inhibitors like Keytruda. The deal values…
BioNTech SE announced the completion of the acquisition of Biotheus, finalizing full global rights to BNT327/PM8002. The closing follows the November 13,…
May 30, 2026 (ASCO 2026): Global interim Phase 2 data from ROSETTA Lung-02 (NCT06712316) for pumitamig (BNT327/BMS-986545) plus chemotherapy in first-line…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
BioNTech announced agreement to acquire Biotheus for $800M upfront (cash + small portion ADS) plus up to $150M in contingent milestones, total up to $950M. Deal deepens BNT327 program, a PD-L1/VEGF-A bispecific antibody being tested in 700+ patients across multiple tumor types as a pan-tumor platform for combinations. BNT327/PM8002 has since received the INN/generic name pumitamig (BMS code BMS-986545); in June 2025 BioNTech partnered it with Bristol Myers Squibb in a global 50/50 co-development/co-commercialization deal ($1.5B upfront, up to ~$11.1B total). As of mid-2026 pumitamig is in a pivotal global Phase 3 program — ROSETTA Lung-01 (first-line extensive-stage SCLC vs atezolizumab+chemo) and ROSETTA Lung-02 (first-line NSCLC vs pembrolizumab+chemo, 1500 mg Q3W dose selected) — with 2026 Phase 2 NSCLC data showing confirmed ORR up to 63.6% (non-squamous) and 72.7% (squamous).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioNTech SE / Biotheus Inc. (Pumai Biotechnology) (this deal) | 2024 | $950M | — |
| BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. | 2023 | $1.7B | — |
| BioNTech SE / Kite Pharma (Gilead Sciences) | 2021 | $250M | — |
| BioNTech SE / CureVac N.V. | 2025 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2024 deals · BioNTech SE deals · Oncology deals